Exciting Developments from BioLineRx and Hemispherian at EANO 2026 Conference

Major Presentation on GLIX1 at EANO 2026

BioLineRx Ltd. and Hemispherian AS are gearing up to present new insights on their promising cancer drug, GLIX1, at the upcoming 21st Meeting of the European Association of Neuro-Oncology (EANO 2026), set for September 24-27 in Rome, Italy. GLIX1 is a cutting-edge treatment primarily aimed at glioblastoma, a highly aggressive form of brain cancer.

Background on GLIX1

BioLineRx, a company known for its innovative therapeutic solutions in oncology and rare diseases, has collaborated with Hemispherian, which specializes in developing small molecule therapies. The preclinical efficacy data for GLIX1, which highlights its potent anti-tumor capabilities, will be a central focus of their presentation. This data stems from various in vivo studies conducted on orthotopic glioblastoma models and offers new hope for patients battling this challenging disease.

Philip Serlin, CEO of BioLineRx, expressed excitement about showcasing their findings at such a prestigious event. He noted that the presentation will not only cover preliminary results but also delve into the detailed design of their first-in-human Phase 1/2a clinical trial.

Spotlight on Preclinical Findings

The GLIX1 data focuses on its role as a TET2 activator, which targets the DNA damage response. Recent findings indicate that GLIX1 exhibited significant anti-tumor activity across multiple GBM models. In particular, researchers are witnessing compelling results in both xenograft models: one being the slower-growing SNB19, and the other the aggressive U87-MG model. GLIX1 treatment led to substantial tumor growth inhibition, showcasing the drug's potential effectiveness in clinical settings.

Specifics of the Studies

In their presentation, the team will share detailed results indicating that GLIX1 was able to achieve brain exposures of 68-85% of plasma levels, which reflects its capacity to penetrate the blood-brain barrier—critical for treating brain tumors. Moreover, participants can look forward to discussions surrounding the dose-dependent correlation between GLIX1 administration and survival benefits in treatment groups, further solidifying the rationale for moving into human trials.

Future Trials and Expectations

Accompanying the presentation of preclinical data will be an e-poster that outlines the ongoing Phase 1/2a trial, which is currently enrolling eligible patients. This clinical trial’s primary objectives include assessing safety, tolerability, and determining the maximum tolerated dose (MTD) while secondary endpoints will explore the drug’s pharmacokinetics and antitumor effectiveness. The e-poster with valuable insights into the clinical trial design will be on display electronically throughout the EANO conference.

Closing Thoughts

In summary, BioLineRx and Hemispherian's upcoming presentations at EANO 2026 are crucial milestones in the development of GLIX1. Their dedicated studies into the drug's efficacy against relentless cancer types could pave the way for new treatment avenues in neuro-oncology. With a well-structured approach and promising data, the teams are hopeful about converting this research into beneficial therapies for patients facing severe health challenges.

For more details on the event and their exciting developments, stay tuned as the conference unfolds.